The diabetes portfolio of Bristol-Myers Squibb Co. (NYSE:BMY) - including products from its proposed acquisition of Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and its partnership with AstraZeneca plc (LSE:AZN; NYSE:AZN) - covers nine of at least 19 targets/mechanisms in development or on the market to treat diabetes. This compares to seven targets/mechanisms in the pipeline at